Introduction {#sec1}
============

Breast cancer is the most common non-keratinocyte cancer in women in the USA, with over 270 000 new cases each year ([@ref1]). Established risk factors for breast cancer include age, reproductive history and family history of disease and can be used to estimate disease risk ([@ref2],[@ref3]). Additionally, and beyond the recognized role of inherited *BRCA* mutation, individual germline genetic variants and even polygenic risk scores from genome-wide association studies have also contributed to breast cancer risk assessment ([@ref4]). Nonetheless, a large gap in the capacity to predict breast cancer risk remains, and the molecular basis of breast cancer risk and carcinogenesis has largely not been studied using target-organ biospecimens from premenopausal women.

Epigenome-wide association studies (EWAS), using surrogate tissues such as peripheral blood DNA, have also had some success testing the relation of DNA methylation with cancer risk ([@ref7]). However, unlike genetic variation and germline alterations that confer cancer risk, cytosine modifications that contribute to cancer risk as disease initiating and promoting events are overwhelmingly tissue-specific. Defining and leveraging knowledge of tissue-specific early DNA methylation alterations for screening or risk models in normal, non-tumor human tissues is challenging for most common tumor types. Yet, use of breast-specific substrate to investigate breast cancer risk has shown promise in early studies measuring cell composition, cytology and candidate gene DNA methylation from nipple aspirate fluid, though as a substrate, nipple aspirate fluid can be challenging to obtain and typically yields very low volume ([@ref10]). Recently, the utility of altered DNA methylation in cancer screening and risk assessment was established in colon cancer as part of the Cologuard multi-target assay where a tissue-specific biospecimen (stool) is obtained and measured without using an invasive procedure ([@ref15]).

The majority of extensive DNA methylation alterations observed in invasive breast cancer compared with normal breast tissue are already present in pre-invasive disease ([@ref16]). In addition, age-related variation in normal breast tissue DNA methylation has been shown to occur at CpG sites that are more likely to be altered in breast tumors ([@ref16]), suggesting that early measures of DNA methylation in the pathologically normal breast have value as a biomarker for future breast cancer risk ([@ref16]). Typically, mammary epithelial cells cannot be accessed without invasive procedures (breast biopsy), lavage or other relatively impractical methods. However, exfoliated mammary epithelial cells (lactocytes, myoepithelial and progenitor/stem cells) are abundant in mature breast milk (as high as 98% of cells) ([@ref19],[@ref20]), providing a tissue-specific substrate obtained without invasive procedure. These cells are an excellent target for biomarker development, and prior candidate gene studies have shown that methylation-induced silencing of tumor suppressor genes in breast milk is related with history of breast biopsy, an established risk factor for breast cancer ([@ref21]). Also as we learn more about human milk as a potential research target, we are now aware of potential sources of variability for these biospecimens ([@ref24]). Given that 85% of 40-year-old women in the USA have given birth ([@ref25]), breast milk is a viable non-invasive source of mammary epithelial cells ([@ref26]). We investigate the relation of early epigenetic alterations with breast cancer risk using cells obtained from breast milk of women who did not develop breast cancer (hereafter named as 'controls') compared with prospectively collected milk specimens from subjects who were later diagnosed with breast cancer.

Results {#sec2}
=======

Genome-scale DNA methylation was measured in breast milk samples from 87 subjects using the Illumina HumanMethylation450 beadchip. Subject demographic and sample details are provided in [Table 1](#TB1){ref-type="table"}. A total of 64 (73%) samples were from cancer-free subjects and 23 were from subjects who had a breast cancer diagnosis of which 20 (87%) were collected prior to diagnosis. Milk samples from subjects with any breast cancer diagnosis were classified according to whether the cancer was in the ipsilateral or contralateral breast. Overall, about 70% of samples from subjects with subsequent breast cancer were collected from the ipsilateral breast (n = 14) and 30% were from the contralateral breast (*n* = 6). Unless stated otherwise, here we summarize the comparison between cancer-free subjects and those with subsequent breast cancer focusing on the ipsilateral breast and exploring the potential effects in the contralateral breast. Results of comparisons between cancer-free subjects with the other three groups are deposited in zenodo ([@ref27]).

###### 

Subject characteristics

  Variable                       *N* (%) or mean \[range\]                         
  ------------------------------ --------------------------- --------------------- ---------
  Age (years)                    33.2 \[23--44\]             36.3 \[29--45\]       0.01
  BMI                            26.5 \[18.2--43.6\]         25.2 \[18.4--38.7\]   0.40
  BMI category                                                                     0.20
   Normal/underweight            28 (43.8)                   8 (34.8)              
   Overweight/obesity            27 (42.2)                   13 (56.5)             
   Missing                       9 (14.1)                    2 (8.7)               
  Breast biopsy                                                                    \<0.001
   No                            50 (78.1)                   0 (0.0)               
   Yes                           14 (21.9)                   23 (100.0)            
  Time since delivery (months)   2.2 \[0--10\]               10.8 \[0.2--20\]      \<0.001
  Parity                         2 \[1--5\]                  2 \[1--4\]            \<0.001
  Milk sample                                                                      N/A
   Ipsilateral                   N/A                         16 (69.6)             
   Contralateral                 N/A                         7 (30.4)              
  Milk collection                                                                  N/A
   Pre-diagnosis                 N/A                         20 (87.0)             
   Post-diagnosis                N/A                         3 (13.0)              

We used a reference-free cell type estimation approach to identify the number of putative cell types and the proportions of each cell type in each breast milk sample. The reference-free method identified five putative cell types in human milk. In unadjusted models, we observed differences in cell type proportions between breast milk samples from women who did not develop breast cancer (controls) compared with those diagnosed with a new breast cancer (ipsilateral or contralateral) for three of the five putative cell types. The proportions of cell types 2 and 3 were higher in subjects with a prospective diagnosis of breast cancer than controls (*P* = 5.2E-06 and 7.1E-04), and the proportion of cell type 4 was lower in milk from subjects with breast cancer compared to controls (*P* = 1.2E-05) ([Fig. 1](#f1){ref-type="fig"}). In these models, differential abundance of putative cell types in controls versus cases was similar irrespective of whether the samples were from the ipsilateral or contralateral breast, or whether the breast cancer diagnosis occurred prior or subsequent to breast milk sample collection (see Additional File, [Supplementary Material, Fig. S1](#sup1){ref-type="supplementary-material"}). After adjusting for maternal age (years), time since delivery (months) and BeadArray slide number, cell type proportions were no longer associated with breast cancer diagnosis. We also explored the cell composition of the samples using a modified reference-based hierarchical EpiDISH approach ([@ref28],[@ref29]). The predominant cells were epithelial cells and 'neutrophils' (granulocytes and other related cells) (Additional File, [Supplementary Material, Fig. S2](#sup1){ref-type="supplementary-material"}).

![Percentage of reference-free cell estimates in subjects with and without breast cancer. Note: here all the samples from both contralateral (*n* = 6) and ipsilateral breast (*n* = 20) are shown in the graph.](ddz301f1){#f1}

DNA methylation was compared using linear mixed effect models adjusted for time since delivery in months, maternal age in years, estimated cell type proportions and array chip with subject as a random effect. We explored potential sources of variability between the ipsilateral new breast cancer and our model covariates, the major sources of variation were time since delivery (*r* = 0.73) and age at donation (*r* = 0.22) and putative cell types 2--4 (see Additional File, [Supplementary Material, Table S1](#sup1){ref-type="supplementary-material"}). We identified 58 significantly differentially methylated CpG sites associated with milk from the ipsilateral breast after correction for multiple comparisons (*q*-value \<0.05). Among these 58 CpGs, two CpGs in island regions and associated one with both the *LRRC61* and *ACTR3C* genes and the other with *SLC18B1* (previously *C6orf192*) were significantly hypermethylated in breast milk from subjects who were later diagnosed with breast cancer ([Fig. 2](#f2){ref-type="fig"}). The remaining 56 CpG sites were significantly hypomethylated in prospectively collected breast milk from the ipsilateral breast of subjects who developed cancer compared with controls ([Fig. 2](#f2){ref-type="fig"}). The most statistically significantly hypomethylated CpG site related to breast cancer diagnosis was located in the island region of the *CLCC1* gene. Additional genes with hypomethylated loci included *TMSB10*, *ZNF584*, *MAP10* (previously *KIAA1383)*, *TRIM27* and *SEPTIN7* (previously *SEPT7*). A total of 32 of these CpGs also were hypomethylated in prospectively collected milk from women who developed cancer in the contralateral breast compared to controls ([Table 2](#TB2){ref-type="table"}). The full set of the unadjusted and adjusted EWAS results are deposited in zenodo ([@ref27]); an overview of the results is available as Additional File, [Supplementary Material, Figure S3](#sup1){ref-type="supplementary-material"}.

![Volcano plots differentially methylated sites in milk from the ipsilateral breast in prospectively diagnosed cancer patients. Note: In red those CpGs that were differentially methylated (*q*-value \<0.05), 56 hypomethylated and 2 hypermethylated. Gene names were added to those CpG sites that overlapped with CpGs differentially methylated in the contralateral breast.](ddz301f2){#f2}

###### 

CpG loci that are hypomethylated in breast cancer

  CpG ID       Gene                  Enhancer   Genomic context   Both breasts[^a^](#tblfn1){ref-type="table-fn"}
  ------------ --------------------- ---------- ----------------- -------------------------------------------------
  cg00954003   *TMSB10*                         Island            Yes
  cg22063056   *CLCC1*                          Island            Yes
  cg04637598                         x          Island            Yes
  cg19286631   *TRIM27*                         Open sea          Yes
  cg14399369   *VRK2*                           Island            Yes
  cg02191044   *MAP10*               x          N-Shore           Yes
  cg26421123   *COMMD5*                         Island            Yes
  cg18453621   *LMX1B*                          Island            Yes
  cg01221484   *ZNF584*                         Island            Yes
  cg15698995   *NAT14*                          Island            Yes
  cg12538369   *SERTAD1*                        Island            Yes
  cg06363887   *UTP3*                           Island            Yes
  cg19337593   *DHPS*                           Island            Yes
  cg21458073   *SEPTIN7*                        Island            Yes
  cg01996304   *ZNF668*                         Island            Yes
  cg02014690   *DGCR6*                          Island            Yes
  cg24104616   *ZNF311*                         Open sea          Yes
  cg03644271   *LDHA*                           Island            Yes
  cg09974136   *RAB34*               x          Island            Yes
  cg14500569   *PTCH1*                          Island            Yes
  cg05698228   *ENC1*                           Island            Yes
  cg09422220   *ELMOD2*                         Island            Yes
  cg24663984   *UBE4A*               x          Island            Yes
  cg02236651   *LIMD2*                          Island            Yes
  cg08790491   *PSMA3-AS1; ARID4A*              Island            Yes
  cg20923184                         x          Open sea          Yes
  cg20605045   *SFXN4*               x          Island            No
  cg14610853   *EEF1A2*                         S-Shelf           Yes
  cg24471039   *RAB3GAP1*                       Open sea          No
  cg09827701   *USP19*                          Island            No
  cg06952862   *NHEJ1*                          S-Shore           Yes
  cg19570943   *MAGOHB*                         Island            Yes
  cg16400434   *PPME1; C2CD3*                   Island            No
  cg01228243   *GPAT4*                          Island            No
  cg12276298   *SEM1; FAM149B1*                 Island            Yes
  cg26973266   *TRAF4*                          Island            No
  cg00496455   *TUBA4A*                         Island            No
  cg18522266   *SMARCA4*                        Island            No
  cg19584875   *KCNK13*                         Island            No
  cg20287461   *TMEM102*                        N-Shore           No
  cg06094142                         x          Open sea          No
  cg26292521   *GATA3-AS1; GATA3*    x          Island            No
  cg09523472   *RAD21*                          Island            Yes
  cg16914272   *H2BC15; H2AC15*                 Island            Yes
  cg04422896   *C12orf43*                       Island            No
  cg04193422   *PON2*                           Island            No
  cg19483159   *DYNLT1*                         S-Shore           No
  cg05677943                         x          Open sea          No
  cg14328761                                    Open sea          No
  cg10291648   *TIRAP*                          Island            No
  cg25977304   *POU2F1*                         Island            No
  cg21077559   *TMEM155; PP12613*               Island            No
  cg03243700   *WDR5*                           Island            No
  cg04799218   *LPCAT3*                         Island            No
  cg07496106   *GPT2*                           Island            No
  cg24717401   *CCM2*                           Island            No

^a^Hypomethylation statistically significant on both ipsilateral and contralateral breast milk samples compared to non-cancer controls or not. For those marked as no, the hypomethylation was significant for the ipsilateral sample only.

We accessed TCGA breast tumor data using cBioportal to determine whether genes we identified as having hypomethylated CpGs related to breast cancer were associated with gene regulation. We found negative correlations between DNA methylation with mRNA expression z-scores (RNA seq) for many of these genes including *ZNF584* (*P* = 2.41E-17), *MAP10* (*P* = 1.61E-76), *TRIM27* (*P* = 6.01E-14), *LIMD2* (*P* = 1.14E-59) and *LDHA* (*P* = 6.06E-06). In contrast, there was little to no correlation between DNA methylation and expression of *CLCC1* (Spearman ρ = −0.03, *P* = 0.5), *TMSB10* (ρ = −0.08, *P* = 0.07) and *SEPTIN7* (ρ = −0.05, *P* = 0.2), see Additional File, [Supplementary Material, Figure S4](#sup1){ref-type="supplementary-material"}. The range of DNA methylation level observed for each CpG tested in the TCGA tumors was comparable to that observed in our samples. When we compared the DNA methylation level change between normal adjacent and breast cancer in TCGA, 22 CpGs from our results followed the same direction in TCGA samples including *TRIM27* and *MAP10* (see Additional File, [Supplementary Material, Table S2](#sup1){ref-type="supplementary-material"}). Of those, seven CpGs were also hypomethylated when comparing normal breast tissue versus breast cancer tissue in the dataset by Teschendorff *et al.* ([@ref18])*.*

Given the preponderance of CpG-specific breast milk DNA hypomethylation associated with breast cancer, and that repeat element hypomethylation is well established in cancer, we further assessed repetitive element methylation. To do so, we inferred Alu (37 subfamilies) and LINE-1 (115 subfamilies) DNA methylation using array data and the repetitive element methylation prediction (REMP), as detailed in the Methods section. None of the individual repetitive elements reached statistical significance after multiple comparison correction. The nominally significant are summarized in Additional File, [Supplementary Material, Table S3](#sup1){ref-type="supplementary-material"}. Mean Alu subfamily methylation was significantly lower in breast cancer cases compared to controls (β = −0.21, *P*-value = 2.9E-4), and mean LINE-1 subfamily methylation was also lower in cases than controls (β = −0.073, *P*-value = 0.10) ([Fig. 3](#f3){ref-type="fig"}).

![Differences in repetitive element CpG methylation by breast cancer status. Note: here all the samples from both contralateral (*n* = 6) and ipsilateral breast (*n* = 20) are shown in the graph.](ddz301f3){#f3}

To evaluate the location in the genome where breast cancer-related DNA methylation alterations in breast milk were occurring, we performed enrichment analyses for both genomic context and gene sets. Differentially methylated CpGs (*q-*value \<0.05) associated with a subsequent diagnosis of breast cancer were enriched for CpG island regions in milk from both the ipsilateral and contralateral breast ([Table 3](#TB3){ref-type="table"}). Among CpGs whose methylation was significantly related with cancer diagnosis we also tested for enrichment of gene sets using the molecular signatures database (MSigDB) v. 6.2, and identified seven gene sets enriched for the 32 CpG sites that were differentially methylated in both ipsilateral and contralateral samples. The top two pathways are related to highly conserved motif clusters matching transcription factor binding sites ([@ref30]). Three pathways are related to upregulation of genes in CD8(+) T lymphocytes, T regulatory cells and dendritic cells. Finally, two gene sets are associated to tumor invasion ([@ref31]) and granulocyte differentiation in acute promyelocytic leukemia ([@ref32]), see Additional File, [Supplementary Material, Table S4](#sup1){ref-type="supplementary-material"}.

###### 

Enrichment for genomic context in CpGs with *q* \< 0.05

  Breast cancer group[^a^](#tblfn2){ref-type="table-fn"}   Island regions       Enhancer regions                       
  -------------------------------------------------------- -------------------- ------------------ ------------------- ---------
  Ipsilateral                                              3.48 (1.75, 7.45)    9.3E-05            1.05 (0.45, 2.18)   8.5E-01
  Contralateral                                            4.28 (1.64, 13.30)   8.6E-04            1.01 (0.30, 2.67)   1.0E+00

^a^Reference level is controls with no breast cancer history.

^b^ *P* determined using the Cochran--Mantel--Haenszel test.

In univariate linear mixed effect analyses we also tested for DNA methylation age acceleration and elevated epigenetic mitotic clock tick rate (epiTOC) in association with breast cancer status. The epiTOC estimates were significantly higher among breast cancer subjects (β = 0.013, *P*-value = 3.2E-04, [Fig. 4A](#f4){ref-type="fig"}); when restricting to the ipsilateral samples the association was still significant (β = 0.017, *P*-value = 5.4E-05). A marginal non-statistically significant increase in age acceleration subjects with breast cancer compared to controls was also observed in new cancer diagnoses using samples from any breast (β = 2.7, *P*-value = 0.071, [Fig. 4B](#f4){ref-type="fig"}), and when restricting to the ipsilateral samples (β = 2.5, *P*-value = 0.1).

![Measures of age inferred from methylation values. (A) Epigenetic mitotic clock tick rate (epiTOC) between controls and subjects who later developed breast cancer. (B) Age acceleration (difference between chronological and DNA methylation age) between controls and subjects who later developed breast cancer. Note: Here all the samples from both contralateral (*n* = 6) and ipsilateral breast (*n* = 20) are shown in the graph.](ddz301f4){#f4}

Discussion {#sec3}
==========

We identified significant differences in DNA methylation after controlling for cell type and other confounders in subjects with a subsequent diagnosis of breast cancer compared with controls. In the subjects who were diagnosed with breast cancer after the milk collection, nearly all of the significantly differentially methylated CpGs were hypomethylated. Several of the genes whose CpG sites were differentially methylated in prospectively diagnosed cases have previously been associated with breast cancer. For example, *TMSB10* is overexpressed in breast cancer cells, has elevated protein expression in serum of breast cancer patients and is elevated with increasing breast cancer stage and distant metastasis ([@ref33]). Linking a systemic marker of breast cancer risk to our tissue-specific approach, promoter CpG island hypomethylation of *ZNF584* was associated with a breast cancer diagnosis both here and in peripheral blood DNA from breast cancer patients ([@ref34]). Further, using TCGA breast tumor data, we showed the functional relationship of *ZNF584* DNA methylation with gene expression. We also observed hypomethylation at CpGs in *SEPTIN7*, *TRIM27*, *LIMD2* and *LDHA,* which have been associated with breast cancer metastasis, invasion and proliferation, ([@ref35]). Apart from *SEPTIN7*, all these genes showed negative correlation between gene expression and DNA methylation in TCGA breast cancer samples, again demonstrating functional consequences of altered DNA methylation to gene regulation. These results support our hypothesis that epigenetic alterations in human milk have utility for non-invasive molecular assessment of breast cancer risk.

Among subjects with incident breast cancer, the group of hypomethylated CpGs found to be significantly differentially methylated in milk samples from both contralateral and ipsilateral breast compared to those from controls was enriched for CpG island regions. Methylation at CpG island regions can reduce gene expression in associated genes ([@ref39]). Since the majority of differentially methylated CpGs were hypomethylated, this may correspond to increased expression of genes with promoters in these regions, and consistent with our observations of local and potentially systemic effects, our pathway enrichment analyses identified both proto-oncogene signatures and immune dysregulation signatures. One pathway with strong enrichment is associated with a motif for the *ELK-1* a regulator of the *c-Fos* proto-oncogene which has been linked to growth suppression in breast cancer cells ([@ref40]). The second pathway includes CpGs related to a motif for *SP-1*, a part of the Kruppel-like family that also has been associated as a prognostic factor in breast cancer ([@ref41]). Three more pathways pointed to genes upregulated in CD8(+) T lymphocytes, activated T-regulatory cells and dendritic cells, cornerstones of tumor immune response in breast cancer murine models ([@ref42]). The remaining two pathways were related to tumor invasion and granulocyte differentiation.

We also observed differences in measures of methylation age including the epiTOC estimator and non-significant differences using the Horvath's methylation age between breast cancer subjects and control subjects. Notably, in our study population, the subjects with a cancer diagnosis were slightly older than control subjects. There have been inconsistent trends of accelerated age in normal breast tissues when using the Horvath methylation age approach ([@ref16]). Accelerated biologic age inferred using DNA methylation has recently been associated with breast cancer risk in a very large prospective study using peripheral blood ([@ref43]). However, to date, unlike peripheral blood, there are no DNA methylation clocks for inference of biologic age that are calibrated specifically to biospecimens from the breast. In the future, larger breast-tissue-specific studies are needed to advance our understanding and opportunity to leverage biologic age estimates for breast cancer risk assessment and primary prevention.

This study has several strengths and limitations. Strengths of our study include the use of prospectively collected specimens, tissue-specific measures of DNA methylation and two independent cohorts. Although some subjects potentially had clinically occult disease when providing a milk specimen, others were not diagnosed until years later. Based on a cohort study of women exposed to breast radiation due to benign disease, the latency between the initiating event and the development of a clinical stage ranged between 10 and 30 years ([@ref44]). In our cohort, the women who later developed breast cancer could have already had an asymptomatic tumor that could be detected in the exfoliated cells in the breast milk. One limitation of this study is sample size, though investigating genome-scale DNA methylation measures in breast milk is novel. One potential limitation is that we pooled controls from two different cohorts processed in different technical batches. Although we controlled for technical differences in our models and used a conservative approach that adjusted for cell estimates which also captures technical differences, we cannot completely exclude some residual technical noise between cohorts affecting our results. In the future, we expect to gather additional information about the cell composition of breast milk samples that will allow the application of improved reference-based approaches (including additional cell subtypes not available in our exploratory approach). This will allow discerning between closely related cell types which currently are collapsed into wider categories (subtypes of epithelial cells and immature/progenitor myeloid cells).

We identified early DNA methylation alterations in breast milk associated with subsequent breast cancer occurrence. These loci were either in genes expressed in breast cancers, related to breast cancer progression or found in peripheral blood samples of women with breast cancer. Importantly, because we identified both overlapping results with work that used peripheral blood as a surrogate biospecimen and results distinct to breast milk, we expect that our tissue-specific approach has high potential for follow-up work. We expect that future investigations of DNA methylation changes present in cells from breast milk from disease-free women will have value for risk assessment and primary prevention of breast cancer, perhaps with specific strength in application to premenopausal disease. However, larger studies are needed to validate our findings and to further establish the utility of breast milk as a biospecimen for understanding the molecular basis of disease risk and prospective risk assessment.

In conclusion, we assessed genome-wide DNA methylation in breast milk from subjects with and without breast cancer; specific loci were hypomethylated in breast cancer subjects compared to control subjects. These differentially methylated regions were more likely to occur in island regions of the genome. Our results suggest that breast milk has utility for prospective assessment of breast cancer risk.

Materials and Methods {#sec4}
=====================

Study population {#sec5}
----------------

Two different study populations were included in this study: (1) women from the 'Molecular Biomarkers for Assessing Breast-Cancer Risk' project at the University of Massachusetts Amherst (UMass) and (2) participants of the New Hampshire Birth Cohort Study (NHBCS) at Dartmouth College. UMass subjects were women older than 18 years. They were either lactating or have recently given birth, and they had a history of either breast biopsy or breast cancer. UMass subjects were asked to provide one or two breast milk samples expressed in a single pumping session. NHBCS participant characteristics have been described previously ([@ref45]). Briefly, NHBCS eligibility criteria included: English speaking, literate and mentally competent women carrying a singleton pregnancy, 18--45 years of age and whose primary source of residential water was a private well. Women who planned to move during pregnancy were excluded from this study. NHBCS participants were asked to bring bilateral breast milk samples to the postpartum follow-up appointment. All study participants provided written informed consent prior to the study according to the guidelines of Institutional Review Board of the University of Massachusetts Amherst and the Committee for the Protection of Human Subjects at Dartmouth. Women in both studies were asked to complete a questionnaire about general health, reproductive health and personal breast biopsy and breast cancer history. Each woman's samples were classified into five different groups: (1) no breast cancer history, (2) healthy breast, contralateral breast cancer before donation, (3) ipsilateral breast cancer diagnosis before donation, (4) healthy breast contralateral cancer diagnosis after donation and (5) sample from the ipsilateral breast with cancer after donation. For this analysis, we report the results of model milk samples from control subjects and from subjects with a subsequent diagnosis of breast cancer.

Sample collection {#sec6}
-----------------

Using a previously described method ([@ref26]), breast milk was processed within 24 h of sample collection to obtain DNA. Briefly, DNA was extracted from 1 to 10 ml of milk from each breast and stored at −20°C until DNA extraction.

DNA extraction and genome-wide DNA methylation array {#sec7}
----------------------------------------------------

DNA was isolated using the Qiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) and bisulfite converted using the EZ DNA Methylation kit (Zymo, Irvine, CA). Samples were randomized across several plates and subsequently subjected to epigenome-wide DNA methylation assessment using Illumina Infinium HumanMethylation450 BeadChip, which measured \~485 000 CpG sites genome-wide (Illumina, San Diego, CA). Microarrays were processed at USC core facility following standard protocols. The data were assembled using GenomeStudio methylation software (Illumina) without normalization as per the manufacturer's instructions. The methylation status for each individual CpG locus (β-value) was calculated as the ratio of fluorescent signals (β = Max(M,0)/\[Max(M,0) + Max(U,0) + 100\]), ranging from 0 (no methylation) to 1 (complete methylation) using the average probe intensity for the methylated (M) and unmethylated (U) alleles. We read the idat files using the minfi R package ([@ref46]). β-values were background corrected using methylumi-noob and normalized using functional normalization.([@ref47]) Our pipeline included array control probes to assess sample quality and evaluate potential problems such as poor bisulfite conversion or color-specific issues for each array as described previously ([@ref48],[@ref49]). All CpG loci on X and Y chromosomes, CpH and loci with potential problems of cross-reactivity, tracking to polymorphisms with minor allele frequencies over 5% for the general population, or common copy number alterations,([@ref50]) were excluded from the analysis, leaving 368 171 autosomal CpG loci in 92 samples. Principal components analysis and multiple dimension scaling were used to identify potential technical batches. Additionally, we used a principal component regression analysis to investigate the top eight principal components in relation to potential batch-associated differences. Subjects with missing covariate data were excluded from modeling, resulting in 87 samples. DNA methylation β-values were logit~2~ transformed to M-values for the analyses ([@ref51]).

Cell mixture analysis {#sec8}
---------------------

Given the lack of cell-specific DNA methylation references for most of the breast epithelial cell subtypes being interrogated (lactocytes, myoepithelial, progenitor cells, among others) ([@ref20]), we were unable to apply a reference-based approach to cell type deconvolution in the EWAS models. Instead, to identify and adjust for potential cell type heterogeneity in the breast milk samples, we used a reference-free decomposition (RefFreeCellMix) of the DNA methylation matrix into cell-type distributions and cell-type methylomes, using the expression *Y* = Μ\*Ω^Τ^ ([@ref52]). We explored a range of *k* cell types from 2 to 10. Note that the decomposition will be based on *Y*, but Yfinal (=*Y* by default) was used to determine the final value of M based on the last iterated value of Ω. We explored the global cell composition of the samples using a modified hierarchical EpiDISH approach. As references we used the epithelial, fibroblast and immune cell matrix included in EpiDISH and for the immune cell composition we used the legacy 450 k library included in FlowSorted.Blood.EPIC ([@ref28],[@ref29]), cell proportions were estimated through robust partial correlations.

Locus-by-locus analysis for detecting differentially methylated CpG loci {#sec9}
------------------------------------------------------------------------

We implemented a locus-by-locus analysis to identify differentially methylated CpG sites between samples obtained from control subjects without breast cancer diagnosis and those from healthy and diseased breasts before or after the cancer development using the R package *limma* ([@ref53]). Five groups were compared: (1) Controls with no breast cancer history, (2) Contralateral Prior Diagnosis (sample from healthy breast of a woman previously diagnosed breast cancer), (3) Ipsilateral Prior Diagnosis (sample from affected breast of a woman previously diagnosed breast cancer), (4) Contralateral New Diagnosis (sample from healthy breast of a woman with incident breast cancer) and (5) Ipsilateral New Diagnosis (sample from affected breast of a woman with incident breast cancer). Briefly, linear mixed effects models were fit to each CpG site separately, with the CpG β-value as the response against the five groups. A random effect for subject was included to control for within subject correlation in subjects with bilateral samples (30 subjects). The models were adjusted for time from delivery (in months), maternal age (in years), RefFreeCellMix proportion estimates (five putative cell types), and the microarray slide to control residual batch confounding. *P*-values were adjusted for multiple comparisons by computing the Benjamini--Hochberg *q*-values ([@ref54]), and we defined loci with *q*-value \< 0.05 to be statistically significant. For this analysis, we focus on CpGs identified as differentially methylated in both prospectively diagnosed groups (ipsilateral and contralateral) and report individual group results in supplemental material ([@ref27]). All analyses were carried out using the R statistical package, version 3.5.0 (Vienna, Austria; [www.r-project.org/](http://www.r-project.org/)) ([@ref55]). We accessed TCGA breast tumor data using cBioportal to determine whether genes we identified as having hypomethylated CpGs related to breast cancer were also associated with gene regulation. Finally, we used public data from TCGA (774 breast cancer samples and 97 normal adjacent breast tissue) and from Teschendorff *et al*. (305 breast cancer samples and 50 normal breast tissue, deposited in GEO, GSE69914) ([@ref18]) to explore whether the CpGs observed in our analyses were following the same directionality when comparing normal breast tissue (or normal-adjacent tissue for TCGA) versus breast cancer tissue.

Repetitive element prediction and analysis {#sec10}
------------------------------------------

We use the package REMP ([@ref56]) to estimate the DNA methylation levels on both *LINE-1* and *Alu* transposons using the information from the DNA methylation microarray. This random forest approach covers 37 *Alu* subfamilies and 115 *LINE-1* subfamilies. We computed the average *Alu* and *LINE-1* methylation levels for each sample, and tested the association with prospectively diagnosed breast cancer, excluding the three samples from subjects with a prior diagnosis of breast cancer. *P*-values were computed using the Kenward--Roger approach.

Enrichment analyses {#sec11}
-------------------

The probes that were differentially methylated were tested for pathway and gene set enrichment using missMethyl ([@ref57]) and the MSigDB v.6.2 curated database ([@ref58]). A minimum of two genes were required for further exploring the specific pathway. We also tested for over- or underrepresentation of differentially methylated CpGs identified in the locus-by-locus analysis in (1) enhancer regions and (2) CpG island regions. Loci with a *q*-value \<0.05 were considered to be statistically significant. Odds ratios, 95% confidence intervals and *P*-values were computed with the Cochran--Mantel--Haenszel test and were adjusted for probe type.

Predicted methylation age and stem cell divisions {#sec12}
-------------------------------------------------

We used Horvath's DNA methylation age estimation algorithm ([@ref59]) to calculate predicted methylation age ($\documentclass[12pt]{minimal}
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}{}$\mathrm{mAge}$\end{document}$) using the agep function from wateRmelon ([@ref60]). Using those estimates, age acceleration was defined as: $\documentclass[12pt]{minimal}
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}{}$\mathrm{Age}\ \mathrm{acceleration}=\mathrm{mAge}-\mathrm{Age}$\end{document}$. We tested for differences in age acceleration between control subjects and subjects with breast cancer using a linear mixed effects model to control for within subject correlations. *P*-values were calculated using the Kenward--Roger approach. Additionally, stem cell divisions were estimated using the epiTOC method ([@ref61]), but only 334 of 385 CpGs were available to calculate estimates. epiTOC estimates were compared between cases and controls using unadjusted linear mixed effect models analogously to the age acceleration models.
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The datasets generated and analyzed during the current study are available in the GEO (<https://www.ncbi.nlm.nih.gov/geo/>) under the accession number GSE133918. We also used the public dataset by Teschendorff *et al.* available under the accession number GSE69914, and the data from TCGA available through <https://gdac.broadinstitute.org/>. The EWAS results (unadjusted and adjusted for confounding covariates) are deposited in Zenodo ([https://doi.org/10.5281/zenodo.3362478](10.5281/zenodo.3362478)).
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